Groundbreaking Experimental Medicine Shows Promise in Treating Resistant High Blood Pressure: AstraZeneca’s Baxdrostat Could Revolutionize Hypertension Therapy

In a groundbreaking development, AstraZeneca’s experimental drug Baxdrostat could soon offer a novel approach for treating resistant or uncontrolled hypertension. The promising results of a recent trial suggest that this medication may provide a much-needed addition to the arsenal of treatments against high blood pressure, as it has been decades since the introduction of new methods for managing the condition.

The findings were presented at the European Society of Cardiology Congress 2025 in Madrid and simultaneously published in the New England Journal of Medicine. The study enrolled 800 adults who continued to experience high blood pressure despite taking two or more medications for at least four weeks, with a systolic blood pressure ranging between 140 and 170 mm Hg.

Blood pressure is measured using millimeters of mercury (mm Hg), consisting of an upper systolic reading and a lower diastolic reading. Normal blood pressure is less than 120/80 mm Hg, while elevated blood pressure ranges from 120 to 129/80 mm Hg. According to recent US guidelines, if lifestyle changes do not effectively reduce blood pressure, individuals with readings of 130/80 mmHg or higher should consider taking medication.

The trial divided participants into three groups: one received 1 mg of baxdrostat, another 2 mg, and a third group took a placebo. All participants continued their existing medications throughout the study. After 12 weeks, approximately 40% of those on baxdrostat achieved healthy blood pressure levels compared to less than 20% in the placebo group.

Those receiving 1 or 2 mg of baxdrostat daily experienced an average reduction of around 9 to 10 mm Hg in their systolic blood pressure, a decrease that studies indicate is sufficient to lower cardiovascular risk. High blood pressure puts excessive strain on blood vessels, making the heart less efficient and impeding essential organ and cell function. Without treatment, hypertension can cause arterial damage, increasing the risk of conditions such as heart attack, stroke, coronary disease, vascular dementia, and cognitive impairments.

Heart disease remains the leading cause of death worldwide, and lowering blood pressure is one of the most effective ways to prevent such fatalities. Approximately half of all US adults suffer from high blood pressure, with about 10% exhibiting resistant hypertension—despite taking multiple medications, they still fail to reach the target blood pressure control level.

Dr. Stacey E. Rosen, volunteer president of the American Heart Association, believes that baxdrostat could be a valuable addition to current treatment options due to its ability to complement other anti-hypertensive medications. Existing therapies work by controlling blood pressure in various ways, including relaxing and widening arteries, removing excess fluid and salt from the body, preventing nervous system stress responses, inhibiting hormone production that constricts blood vessels, and keeping calcium away from heart and artery cells to reduce their workload.

Baxdrostat’s side effects were generally mild in the study, with the most common issues being abnormalities in potassium and sodium levels, although these instances were rare. Unlike current treatments, baxdrostat targets aldosterone—a hormone produced by the adrenal glands that helps regulate salt and maintain water balance in the body. In some cases, excessive aldosterone production can lead to water and salt retention, raising blood pressure.

Dr. Jenifer Brown, one of the lead investigators and co-author of the study, emphasizes the potential impact of baxdrostat on patients with resistant hypertension or those who experience side effects from existing medications. “We’ve had the same tools as clinicians for many years,” says Dr. Brown. “I would be excited to have an option like this.”

An editorial accompanying the publication calls for further research to identify which patients are likely to respond best to baxdrostat and to provide long-term data on its effectiveness. If the medication proves effective in the long term, it could become a cornerstone of therapy for resistant hypertension. AstraZeneca plans to submit the trial data to regulatory agencies before the end of 2025.